Related Experiment Video
Updated: Aug 15, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of
F X E Gruber1, T Lamark, A Anonli
1Department of Immunology and Transfusion Medicine, University Hospital of Northern Norway, University of Tromsø, Tromsø, Norway. franz.gruber@unn.no
Abstract:
Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in the ABL gene encoding the ATP binding region likely to cause disease relapse. Early diagnosis and monitoring of these mutations may be important in order to prevent rapid expansion of resistant clones. We describe a quantitative mutation-specific PCR assay based on the readily available Taqman platform. Selectivity for the mutated target is conferred by mutation-specific primers destabilised by additional mismatches. The assay can be carried out in parallel to standard BCR-ABL quantification and is therefore more quickly compared to standard sequencing procedures. The sensitivity of the assay reaches 0.1%. It also allows for quantitative assessment of mutated clones. By analysing sequential samples of resistant subjects, we show how mutated clones were selected, maintained or deselected depending on the individual treatment setting. The high sensitivity and practical merits of this method makes it a good candidate for prospective molecular surveillance of patients at high risk for imatinib resistance.
Insights
A new quantitative PCR assay can detect imatinib-resistant ABL mutations in chronic myeloid leukemia (CML) patients early. This aids in monitoring resistant clones and preventing relapse.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacogenomics
Background:
- Imatinib resistance in chronic myeloid leukemia (CML) is often linked to ABL gene mutations.
- These mutations can lead to disease relapse, necessitating early detection and monitoring.
Purpose of the Study:
- To develop and validate a quantitative, mutation-specific PCR assay for detecting ABL mutations.
- To enable early diagnosis and monitoring of imatinib resistance in CML patients.
Main Methods:
- A quantitative mutation-specific PCR assay using the Taqman platform.
- Mutation-specific primers with destabilizing mismatches for enhanced selectivity.
- Parallel analysis with standard BCR-ABL quantification.
Main Results:
- The assay achieves a sensitivity of 0.1% for detecting mutated clones.
- It allows for quantitative assessment of mutated clone dynamics.
- Sequential analysis revealed selection, maintenance, or deselection of mutated clones based on treatment.
Conclusions:
- The developed PCR assay is highly sensitive and practical for monitoring imatinib resistance.
- It is a valuable tool for prospective molecular surveillance in high-risk CML patients.
- Early detection of ABL mutations can guide treatment adjustments and prevent relapse.
